Spyre shares fall after Phase 2 RA data misses internal bar

What happened

Spyre Therapeutics, a clinical-stage biotechnology company developing treatments for inflammatory bowel disease and other autoimmune conditions, announced topline results from its Phase 2 SKYWAY-RA substudy of SPY072 in rheumatoid arthritis (RA). According to the company announcement, both doses of SPY072 showed statistically significant improvements versus placebo on some endpoints, including change from baseline in DAS28-CRP, a measure of disease activity. However, the company stated that the magnitude of effect did not meet its internal threshold to prioritize monotherapy development in RA, and it is shifting focus to psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and other indications. Shares fell sharply after hours, though the regular-session close on August 25 was $107.36, up 0.67% from the prior close of $106.65.

The news was reported by MarketScreener, which cited the company's announcement, and by Investing.com, which noted the stock tumble. The company had earlier in August expanded its pipeline with SPY772, a new program for hidradenitis suppurativa, pairing SPY072 with a novel agent, according to TradingView and Simply Wall St reports.

Why it matters

SPY072 is a lead pipeline candidate for Spyre, which focuses on inflammatory diseases. A clinical setback in a key indication like RA can prompt investors to reassess the company's prospects and may shift pipeline priorities. The company's decision to pivot away from RA monotherapy and toward other indications reflects how trial results can reshape a biotech's strategy. The stock's after-hours decline suggests the market viewed the data as disappointing, despite the statistical significance on some endpoints.

What this means

Phase 2 trials are mid-stage studies that test a drug's effectiveness and safety in a larger group of patients. The SKYWAY-RA substudy is part of a broader program evaluating SPY072, which is an anti-TL1A antibody designed to block a protein involved in inflammation. DAS28-CRP is a composite score measuring joint tenderness, swelling, and blood markers; a statistically significant change means the improvement is unlikely to be due to chance. However, companies often set internal thresholds for what they consider clinically meaningful, and missing that bar can lead to deprioritizing a program even if some endpoints hit statistical significance.

The company said SPY072 was well tolerated, which is important for safety. Spyre's decision to focus on PsA, axSpA, and other indications suggests it sees more promise in those areas. For readers following the story, the next step is to watch for future readouts from Spyre's ongoing studies, such as the SKYLIGHT trial in hidradenitis suppurativa, which the company started in August. Investing.com noted the stock tumble but did not provide additional details on future plans.